Literature DB >> 25061063

Comparison of Dexmedetomidine Versus Propofol on Hospital Costs and Length of Stay.

Asad E Patanwala1, Brian L Erstad2.   

Abstract

OBJECTIVE: The objective of this evaluation was to compare total hospital costs and length of stay of critically ill patients who received dexmedetomidine versus propofol for sedation in the intensive care unit (ICU).
METHODS: This was a retrospective quality improvement evaluation at a tertiary care, academic medical center in the United States. Data were retrieved for patients discharged between April 2012 and June 2013. Patients were included if they were admitted to the ICU, were 18 years of age or older, and received dexmedetomidine or propofol for sedation. Multivariate regression models were developed to determine the association between sedative type and hospital costs, ICU length of stay, and hospital length of stay.
RESULTS: The final cohort included 3294 patients. Of these, 2685 received propofol and 609 received dexmedetomidine. The median hospital cost was US$31 041 (interquartile range [IQR] US$17 963-US$57 826) in the propofol group and US$46 716 (IQR US$31 247 to US$85 490) in the dexmedetomidine group (P < .001). The median ICU length of stay was 2 days (IQR 1-6 days) and 4 days (IQR 2-9 days) in the propofol and dexmedetomidine groups, respectively (P < .001). Overall, hospital length of stay was 8 days (IQR 4-15 days) and 9 days (IQR 5-18 days) in the 2 groups, respectively (P < .001). In the multivariate analyses, dexmedetomidine use was associated with increased costs, ICU length of stay, and hospital length of stay (P < .001 for each outcome).
CONCLUSIONS: In this academic medical center, dexmedetomidine use was associated with higher costs when compared to propofol for sedation in the ICU. Also, use of dexmedetomidine was associated with increased lengths of ICU and hospital stay. Future prospective trials are needed to confirm these findings.
© The Author(s) 2014.

Entities:  

Keywords:  costs and cost analysis; critical care; dexmedetomidine; propofol

Mesh:

Substances:

Year:  2014        PMID: 25061063     DOI: 10.1177/0885066614544452

Source DB:  PubMed          Journal:  J Intensive Care Med        ISSN: 0885-0666            Impact factor:   3.510


  6 in total

1.  Cost-Minimization Analysis of Dexmedetomidine Compared to Other Sedatives for Short-Term Sedation During Mechanical Ventilation in the United States.

Authors:  Jyoti Aggarwal; Jacqueline Lustrino; Jennifer Stephens; Diana Morgenstern; Wing Yu Tang
Journal:  Clinicoecon Outcomes Res       Date:  2020-07-28

Review 2.  Comparison of Dexmedetomidine Versus Propofol in Mechanically Ventilated Patients With Sepsis: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Hua-Ze Ding; Yi-Ling Dong; Kai-Yue Zhang; Jia-Yu Bai
Journal:  Front Pharmacol       Date:  2022-05-26       Impact factor: 5.988

3.  Dexmedetomidine versus morphine infusion following laparoscopic bariatric surgery: effect on supplemental narcotic requirement during the first 24 h.

Authors:  Sami Abu-Halaweh; Firas Obeidat; Anthony R Absalom; Abdelkareem AlOweidi; Mahmood Abu Abeeleh; Ibrahim Qudaisat; Fay Robinson; Keira P Mason
Journal:  Surg Endosc       Date:  2015-11-05       Impact factor: 4.584

4.  Dexmedetomidine versus midazolam and propofol for sedation in critically ill patients: Mining the Medical Information Mart for Intensive Care data.

Authors:  Yiyan Song; Shaowei Gao; Wulin Tan; Zeting Qiu; Huaqiang Zhou; Yue Zhao
Journal:  Ann Transl Med       Date:  2019-05

5.  Efficacy of dexmedetomidine for treatment of patients with sepsis: A meta-analysis of randomized controlled trials.

Authors:  Wen-Qing Zhang; Po Xu; Xiao-Hong Zhan; Peng Zheng; Wei Yang
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

Review 6.  Smooth Extubation and Smooth Emergence Techniques: A Narrative Review.

Authors:  Tiffany H Wong; Garret Weber; Apolonia E Abramowicz
Journal:  Anesthesiol Res Pract       Date:  2021-01-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.